Literature DB >> 33388215

Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints.

Martina Kreileder1, Ian Barrett2, Claus Bendtsen2, Donal Brennan3, Walter Kolch4.   

Abstract

Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) have been hailed as major advances in cancer therapeutics; however, in many cancers response rates remain low. Extensive research efforts are underway to improve the efficacy of ICIs. The signaling pathways regulated by immune checkpoints (ICs) may be an important lever as they interfere with T-cell activation when activated by ICIs. Here, we review the current understanding of T-cell receptor signaling and their intersection with IC signaling pathways. As these signaling processes are highly dynamic and controlled by intricate spatiotemporal mechanisms, we focus on aspects of kinetic regulation that are modulated by ICs. Recent advances in computational modeling and experimental methods that can resolve spatiotemporal dynamics provide insights that reveal molecular mechanisms and new potential approaches for improving the design and application of ICIs.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  T-cell receptor signaling; immune checkpoint signaling; immunotherapy; network dynamics; tumor microenvironment

Mesh:

Year:  2020        PMID: 33388215     DOI: 10.1016/j.tcb.2020.12.001

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  7 in total

Review 1.  Allostery, and how to define and measure signal transduction.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Biophys Chem       Date:  2022-01-29       Impact factor: 2.352

Review 2.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

3.  Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.

Authors:  Yufang Hou; Rixin Zhang; Jinbao Zong; Weiqi Wang; Mingxuan Zhou; Zheng Yan; Tiegang Li; Wenqiang Gan; Silin Lv; Zifan Zeng; Min Yang
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

4.  Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.

Authors:  Chen Xiong; Zhihuai Wang; Guifu Wang; Chi Zhang; Shengjie Jin; Guoqing Jiang; Dousheng Bai
Journal:  Invest New Drugs       Date:  2021-05-03       Impact factor: 3.850

Review 5.  TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.

Authors:  Jinah Yeo; Minkyung Ko; Dong-Hee Lee; Yoon Park; Hyung-Seung Jin
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

Review 6.  Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.

Authors:  Nagaja Capitani; Laura Patrussi; Cosima T Baldari
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

7.  Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response.

Authors:  Can Liu; Timothy Qi; J Justin Milner; Yong Lu; Yanguang Cao
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.